- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00787969
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To assess the efficacy and safety of the combination of rituximab, cladribine, and temsirolimus for newly diagnosed mantle cell lymphoma.
II. To determine the maximum tolerated dose (MTD) of temsirolimus combined with a fixed dose and schedule of rituximab and cladribine. (Phase I) III. To assess the efficacy of the combination of rituximab, cladribine, and temsirolimus for newly diagnosed mantle cell lymphoma with the proportion of complete responses as the primary endpoint. (Phase II)
SECONDARY OBJECTIVES:
I. To assess other measures of efficacy of the regimen including progression free survival, duration of response, and overall survival.
II. To assess the toxicity profile of the combination of rituximab, cladribine, and temsirolimus.
III. To assess efficacy using traditional lymphoma parameters and absolute lymphocyte count.
IV. To assess metabolic markers (hyperglycemia, hyperlipidemia) as markers of mammalian target of rapamycin (mTOR) inhibition using the glucose and lipid measurements being performed in the clinical laboratory as part of routine care.
V. To correlate response with serum free light chains, single nucleotide polymorphisms (SNPs) in host immune genes, vitamin D metabolites, and phosphatidylinositide 3-kinase (PI3K) pathway member expression.
VI. As part of ongoing research for North Central Cancer Treatment Group (NCCTG) lymphoma studies, paraffin-embedded tissue blocks/slides and blood products will be banked for future studies.
OUTLINE: This is a phase I, dose-escalation study of temsirolimus followed by a phase II study.
Patients receive rituximab intravenously (IV) on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim subcutaneously (SC) on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 4 months for 3 years.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85259-5499
- Mayo Clinic Scottsdale
-
-
Illinois
-
Bloomington, Illinois, Forenede Stater, 61701
- Illinois CancerCare - Bloomington
-
Bloomington, Illinois, Forenede Stater, 61701
- St. Joseph Medical Center
-
Canton, Illinois, Forenede Stater, 61520
- Illinois CancerCare - Canton
-
Canton, Illinois, Forenede Stater, 61520
- Graham Hospital
-
Carthage, Illinois, Forenede Stater, 62321
- Memorial Hospital
-
Carthage, Illinois, Forenede Stater, 62321
- Illinois CancerCare - Carthage
-
Eureka, Illinois, Forenede Stater, 61530
- Illinois CancerCare - Eureka
-
Eureka, Illinois, Forenede Stater, 61530
- Eureka Community Hospital
-
Galesburg, Illinois, Forenede Stater, 61401
- Illinois CancerCare - Galesburg
-
Galesburg, Illinois, Forenede Stater, 61401
- Galesburg Clinic, PC
-
Havana, Illinois, Forenede Stater, 62644
- Mason District Hospital
-
Havana, Illinois, Forenede Stater, 62644
- Illinois CancerCare - Havana
-
Kewanee, Illinois, Forenede Stater, 61443
- Illinois CancerCare - Kewanee Clinic
-
Macomb, Illinois, Forenede Stater, 61455
- Illinois CancerCare - Macomb
-
Macomb, Illinois, Forenede Stater, 61455
- Mcdonough District Hospital
-
Monmouth, Illinois, Forenede Stater, 61462
- Illinois CancerCare - Monmouth
-
Monmouth, Illinois, Forenede Stater, 61462
- OSF Holy Family Medical Center
-
Normal, Illinois, Forenede Stater, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, Forenede Stater, 61761
- Community Cancer Center
-
Normal, Illinois, Forenede Stater, 61761
- Illinois CancerCare - Community Cancer Center
-
Ottawa, Illinois, Forenede Stater, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, Forenede Stater, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, Forenede Stater, 61554
- Cancer Treatment Center at Pekin Hospital
-
Pekin, Illinois, Forenede Stater, 61603
- Illinois CancerCare - Pekin
-
Peoria, Illinois, Forenede Stater, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forenede Stater, 61614
- Proctor Hospital
-
Peoria, Illinois, Forenede Stater, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, Forenede Stater, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, Forenede Stater, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, Forenede Stater, 61354
- Illinois CancerCare - Peru
-
Peru, Illinois, Forenede Stater, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, Forenede Stater, 61356
- Perry Memorial Hospital
-
Princeton, Illinois, Forenede Stater, 61356
- Illinois CancerCare - Princeton
-
Spring Valley, Illinois, Forenede Stater, 61362
- Illinois CancerCare - Spring Valley
-
-
Indiana
-
Elkhart, Indiana, Forenede Stater, 46515
- Elkhart General Hospital
-
Elkhart, Indiana, Forenede Stater, 46514-2098
- Elkhart Clinic, LLC
-
Elkhart, Indiana, Forenede Stater, 46514
- Michiana Hematology-Oncology, PC - Elkhart
-
Kokomo, Indiana, Forenede Stater, 46904
- Howard Community Hospital
-
La Porte, Indiana, Forenede Stater, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Mishawaka, Indiana, Forenede Stater, 46545-1470
- Michiana Hematology-Oncology, PC - South Bend
-
Mishawaka, Indiana, Forenede Stater, 46545-1470
- Saint Joseph Regional Medical Center
-
Plymouth, Indiana, Forenede Stater, 46563
- Michiana Hematology Oncology PC - Plymouth
-
South Bend, Indiana, Forenede Stater, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, Forenede Stater, 46601
- CCOP - Northern Indiana CR Consortium
-
Westville, Indiana, Forenede Stater, 46391
- Michiana Hematology Oncology PC - La Porte
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- McFarland Clinic, PC
-
Cedar Rapids, Iowa, Forenede Stater, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, Forenede Stater, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive, Iowa, Forenede Stater, 50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines, Iowa, Forenede Stater, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Forenede Stater, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Forenede Stater, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, Forenede Stater, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Mason City, Iowa, Forenede Stater, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Sioux City, Iowa, Forenede Stater, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, Forenede Stater, 51102
- Mercy Medical Center - Sioux City
-
Sioux City, Iowa, Forenede Stater, 51104
- St. Luke's Regional Medical Center
-
-
Kansas
-
Chanute, Kansas, Forenede Stater, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, Forenede Stater, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, Forenede Stater, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, Forenede Stater, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Forenede Stater, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Forenede Stater, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, Forenede Stater, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Forenede Stater, 67901
- Cancer Center of Kansas, PA - Liberal
-
Newton, Kansas, Forenede Stater, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, Forenede Stater, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, Forenede Stater, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, Forenede Stater, 67401
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, Forenede Stater, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, Forenede Stater, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, Forenede Stater, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, Forenede Stater, 67214
- CCOP - Wichita
-
Wichita, Kansas, Forenede Stater, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, Forenede Stater, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, Forenede Stater, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Battle Creek, Michigan, Forenede Stater, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, Forenede Stater, 49307
- Mecosta County Medical Center
-
Escanaba, Michigan, Forenede Stater, 49431
- Green Bay Oncology, Limited - Escanaba
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, Forenede Stater, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Iron Mountain, Michigan, Forenede Stater, 49801
- Dickinson County Healthcare System
-
Muskegon, Michigan, Forenede Stater, 49443
- Mercy General Health Partners
-
Niles, Michigan, Forenede Stater, 49120
- Michiana Hematology Oncology PC - Niles
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Lakeside Cancer Specialists, PLLC
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Traverse City, Michigan, Forenede Stater, 49684
- Munson Medical Center
-
Wyoming, Michigan, Forenede Stater, 49519
- Metro Health Hospital
-
-
Minnesota
-
Burnsville, Minnesota, Forenede Stater, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Forenede Stater, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, Forenede Stater, 55805
- CCOP - Duluth
-
Duluth, Minnesota, Forenede Stater, 55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth, Minnesota, Forenede Stater, 55805
- Miller - Dwan Medical Center
-
Edina, Minnesota, Forenede Stater, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Forenede Stater, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, Forenede Stater, 55350
- Hutchinson Area Health Care
-
Maplewood, Minnesota, Forenede Stater, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, Forenede Stater, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, Forenede Stater, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, Forenede Stater, 55422-2900
- Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic Cancer Center
-
Saint Louis Park, Minnesota, Forenede Stater, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, Forenede Stater, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, Forenede Stater, 55102
- United Hospital
-
Saint Paul, Minnesota, Forenede Stater, 55101
- Regions Hospital Cancer Care Center
-
Shakopee, Minnesota, Forenede Stater, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
Stillwater, Minnesota, Forenede Stater, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Forenede Stater, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Forenede Stater, 56201
- Willmar Cancer Center at Rice Memorial Hospital
-
Woodbury, Minnesota, Forenede Stater, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
-
Montana
-
Billings, Montana, Forenede Stater, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, Forenede Stater, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, Forenede Stater, 59107-7000
- Billings Clinic - Downtown
-
Billings, Montana, Forenede Stater, 59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman, Montana, Forenede Stater, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, Forenede Stater, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, Forenede Stater, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, Forenede Stater, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Havre, Montana, Forenede Stater, 59501
- Northern Montana Hospital
-
Helena, Montana, Forenede Stater, 59601
- St. Peter's Hospital
-
Kalispell, Montana, Forenede Stater, 59901
- Kalispell Regional Medical Center
-
Kalispell, Montana, Forenede Stater, 59901
- Glacier Oncology, PLLC
-
Kalispell, Montana, Forenede Stater, 59901
- Kalispell Medical Oncology at KRMC
-
Missoula, Montana, Forenede Stater, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Dakota
-
Bismarck, North Dakota, Forenede Stater, 58501
- Bismarck Cancer Center
-
Bismarck, North Dakota, Forenede Stater, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, Forenede Stater, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, Forenede Stater, 58502
- St. Alexius Medical Center Cancer Center
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater, 57701
- Rapid City Regional Hospital
-
-
Wisconsin
-
Green Bay, Wisconsin, Forenede Stater, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Forenede Stater, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Forenede Stater, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, Forenede Stater, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Manitowoc, Wisconsin, Forenede Stater, 54221-1450
- Holy Family Memorial Medical Center Cancer Care Center
-
Marinette, Wisconsin, Forenede Stater, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls, Wisconsin, Forenede Stater, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sheboygan, Wisconsin, Forenede Stater, 53081
- St. Nicholas Hospital
-
Sturgeon Bay, Wisconsin, Forenede Stater, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
Wyoming
-
Sheridan, Wyoming, Forenede Stater, 82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically confirmed mantle cell lymphoma (MCL); the diagnosis must be confirmed by NCCTG pre-registration pathology review by Dr. Paul Kurtin or his designate; it is recommended that the biopsy be an excisional biopsy, but adequate core-needle biopsies will be accepted as long as they are considered adequate for registration by Dr. Kurtin or his designate; the tumor must be cyclin D-1 positive by immunohistochemistry or have evidence of a t(11;14) translocation by fluorescence based in situ hybridization (FISH) or cytogenetics
Measurable or assessable disease, defined as at least one of the following:
- A lymph node or tumor mass that is >= 2.0 cm in at least one dimension by positron emission tomography (PET)/computed tomography (CT), CT, magnetic resonance imaging (MRI), or plain radiograph imaging
- Splenic enlargement may be used as a measurable parameter if the spleen is palpable >= 3 cm below the left costal margin
- Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2, or 3
- Life expectancy >= 12 weeks
- Absolute neutrophil count (ANC) >= 1,500/mm³
- Platelet count (PLT) >= 100,000/mm³
- Serum creatinine =< 2.0 mg/dL
- Serum total bilirubin (or direct bilirubin if total is abnormal) =< institutional upper limit of normal (ULN) with or without secondary liver involvement
- Serum glutamic oxaloacetic transaminase (SGOT) =< 3 x institutional ULN (exception: if there is liver involvement, SGOT must be =< 5 x institutional ULN)
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Willingness to return to NCCTG enrolling institution for follow-up
- Willingness to provide the blood specimens as required by the protocol
- Willingness to provide tissue specimens as required by the protocol
- Willing to return to NCCTG enrolling institution for follow-up
- Willing to provide blood and tissue specimens as required by the protocol
- Willing to abstain from eating grapefruit or drinking grapefruit juice
- Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study
Exclusion Criteria
- Any prior therapy for mantle cell non-Hodgkin lymphoma including radiation therapy; exception: patient may have undergone a splenectomy for diagnosis, cytopenia, or systematic splenomegaly
- Active or uncontrolled infection
Any of the following cardiac conditions:
- Uncontrolled high blood pressure
- Unstable angina
- Active congestive heart failure
- Myocardial infarction =< 6 months
- Serious uncontrolled cardiac arrhythmia
- Known central nervous system (CNS) involvement
Any of the following:
- Pregnant women or women of reproductive ability who are unwilling to use effective contraception while taking the drug and for 12 months after stopping treatment
- Nursing women
- Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 12 months after stopping treatment
- Medical or psychiatric conditions which, in the opinion of the investigator, make the patient a poor risk for participation
- Known to be human immunodeficiency virus (HIV) positive; HIV testing is not required but should be done if clinically indicated; HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study
- Concurrent malignancy =< 5 years ago; exceptions: carcinoma in situ of the cervix, resected basal cell or squamous cell carcinomas of the skin, or prostate cancer that is in remission following a radical retropubic prostatectomy or radiation therapy; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
- Known hypersensitivity to rituximab or its components, or to murine proteins
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
- Prior treatment with an mTOR inhibitor
- Autologous or allogeneic stem cell transplant planned as part of initial therapy
- Receiving enzyme-inducing antiepileptic drugs (enzyme inducing anti-epileptic drugs [EIAEDs]; e.g., phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, phenobarbital, or primidone); any other potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer such as rifampin, glucocorticoids at greater than adrenal replacement levels, or St. John's wort; or receiving strong CYP3A4 inhibitors * Note: if these agents are discontinued, temsirolimus therapy can begin >= 7 days after discontinuation of such agent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Treatment (rituximab, cladribine, temsirolimus)
Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5.
Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6.
Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Give IV
Give IV
Give IV
Give SC
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of dose limiting toxicity incidents as per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 3.0 (Phase I)
Tidsramme: 28 days
|
28 days
|
Proportion of complete tumor responses defined as complete remission (CR) as the objective status (Phase II)
Tidsramme: Up to 5 years
|
Up to 5 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Samlet overlevelse
Tidsramme: op til 5 år
|
op til 5 år
|
Overlevelsestid
Tidsramme: Op til 5 år
|
Op til 5 år
|
Progression-free survival (PFS)
Tidsramme: up to 5 years
|
up to 5 years
|
Time to disease progression
Tidsramme: up to 5 years
|
up to 5 years
|
Duration of response, defined as date at which the patient's objective status is first noted to be either a CR or partial remission to the date progression is documented
Tidsramme: Up to 5 years
|
Up to 5 years
|
Frequency and severity of adverse events assessed by CTCAE v3.0
Tidsramme: Up to 5 years
|
Up to 5 years
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: David J. Inwards, MD, Mayo Clinic
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom
- Lymfom, kappecelle
- Lægemidlers fysiologiske virkninger
- Anti-infektionsmidler
- Antirheumatiske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, immunologiske
- Antibakterielle midler
- Antibiotika, antineoplastisk
- Antifungale midler
- Rituximab
- Sirolimus
- Cladribin
Andre undersøgelses-id-numre
- NCCTG-N078D
- NCI-2009-00669 (Registry Identifier: CTRP (Clinical Trials Reporting System))
- CDR0000619329 (Registry Identifier: PDQ (Physician Data Query))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Pegfilgrastim
-
Coherus Biosciences, Inc.Community Clinical Oncology Research Network, LLCUkendtFebril neutropeni | Ikke-myeloid malignitetForenede Stater
-
Dr. Reddy's Laboratories LimitedUkendt
-
Academisch Ziekenhuis MaastrichtZonMw: The Netherlands Organisation for Health Research and DevelopmentAfsluttetBrystkræft | Febril neutropeni | KemoterapiHolland
-
Nanogen Pharmaceutical Biotechnology Joint Stock...Afsluttet
-
Kyowa Kirin Co., Ltd.Afsluttet
-
AmgenAfsluttetNon-Hodgkins lymfom
-
Wake Forest University Health SciencesAtrium Health Levine Cancer InstituteRekrutteringBrystForenede Stater
-
Cancer Institute and Hospital, Chinese Academy...Afsluttet
-
Green Cross CorporationSymyooAfsluttet
-
Rabin Medical CenterTel-Aviv Sourasky Medical Center; Soroka University Medical CenterUkendt